Literature DB >> 15160334

The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.

Dennis B Cornfield1, Juan P Palazzo, Gordon F Schwartz, Shanth A Goonewardene, Albert J Kovatich, Inna Chervoneva, Terry Hyslop, Roland Schwarting.   

Abstract

BACKGROUND: A number of conventional histopathologic features have been associated with recurrence of ductal carcinoma in situ (DCIS) after surgery alone and are included in the Van Nuys Pathologic Classification and Prognostic Index. To the authors' knowledge, very little is known regarding the prognostic significance of the many biologic markers that have been studied in DCIS in the past decade.
METHODS: Clinical and pathologic data were analyzed from 151 patients who underwent wide local excision alone for DCIS that was diagnosed by mammography or as an incidental finding between 1982 and 2000. Using local disease recurrence as an endpoint, the authors sought to determine the prognostic significance of a large number of histopathologic parameters as well as biologic markers (estrogen receptor [ER], progesterone receptor [PR], p53, HER-2/neu, Ki-67, p21, and bcl-2), as determined by immunohistochemical staining of contemporary or archival tissue.
RESULTS: With a median follow-up of 65 months, 42 recurrences were reported to occur between 11 months and 97 months after definitive surgery. In a univariate analysis, tumor size, Van Nuys pathologic classification, and degree of necrosis demonstrated significant correlations with the rate of recurrence. Tumor size, necrosis, nuclear grade, and comedonecrosis were found to be associated significantly with the time to disease recurrence. None of the biologic markers demonstrated a significant association with the rate of recurrence or the time to disease recurrence. In a multivariate analysis, only large tumor size (Van Nuys 2 or 3) and higher degrees of necrosis (Van Nuys 2 or 3) were found to be associated significantly with both the rate of recurrence and the time to recurrence. No biologic marker showed a significant correlation with recurrence. Using Classification and Regression-Tree Analysis and Tree-Structured Survival Analysis, PR > 3.5% and bcl-2 < 97.5% were associated with a higher recurrence rate in the subgroup of patients with small tumor size (Van Nuys size 1) and higher degrees of tumor necrosis (Van Nuys 2 or 3).
CONCLUSIONS: The current results confirmed the value of conventional histopathologic parameters, as outlined in the Van Nuys classification system, in predicting local recurrence of DCIS. Using traditional logistic analyses, no significant correlation was found between a variety of biologic markers and disease recurrence. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160334     DOI: 10.1002/cncr.20260

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

2.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

3.  Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ.

Authors:  Matthew W Conklin; Ronald E Gangnon; Brian L Sprague; Lisa Van Gemert; John M Hampton; Kevin W Eliceiri; Jeremy S Bredfeldt; Yuming Liu; Nuntida Surachaicharn; Polly A Newcomb; Andreas Friedl; Patricia J Keely; Amy Trentham-Dietz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

4.  Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma.

Authors:  Georgi Atanasov; Corinna Dietel; Linda Feldbrügge; Christian Benzing; Felix Krenzien; Andreas Brandl; Elli Mann; Julianna Paulina Englisch; Katrin Schierle; Simon C Robson; Katrin Splith; Mehmet Haluk Morgul; Anja Reutzel-Selke; Sven Jonas; Andreas Pascher; Marcus Bahra; Johann Pratschke; Moritz Schmelzle
Journal:  Oncoimmunology       Date:  2017-06-28       Impact factor: 8.110

5.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Authors:  Karla Kerlikowske; Annette M Molinaro; Mona L Gauthier; Hal K Berman; Fred Waldman; James Bennington; Henry Sanchez; Cynthia Jimenez; Kim Stewart; Karen Chew; Britt-Marie Ljung; Thea D Tlsty
Journal:  J Natl Cancer Inst       Date:  2010-04-28       Impact factor: 13.506

6.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

7.  Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma.

Authors:  Kathryn C Behling; Amy Tang; Boris Freydin; Inna Chervoneva; Sameep Kadakia; Gordon F Schwartz; Hallgeir Rui; Agnieszka K Witkiewicz
Journal:  Breast Cancer Res Treat       Date:  2010-11-19       Impact factor: 4.872

Review 8.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

9.  A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression.

Authors:  Kerri-Ann Norton; Michael Wininger; Gyan Bhanot; Shridar Ganesan; Nicola Barnard; Troy Shinbrot
Journal:  J Theor Biol       Date:  2009-12-16       Impact factor: 2.691

Review 10.  The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast.

Authors:  Csaba Polgár; Zsuzsanna Kahán; Zsolt Orosz; Gabriella Gábor; Janaki Hadijev; Gábor Cserni; Janina Kulka; Nóra Jani; Zoltán Sulyok; György Lázár; Gábor Boross; Csaba Diczházi; Eva Szabó; Zsolt László; Zoltán Péntek; Tibor Major; János Fodor
Journal:  Pathol Oncol Res       Date:  2008-04-26       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.